Sigvotatug Vedotin is an antibody-drug conjugate (ADC) designed to selectively target integrin alphavbeta6-positive tumor cells through an engineered antibody with high specificity. Sigvotatug Vedotin employs a protease-cleavable linker that delivers the cytotoxic payload monomethyl auristatin E (MMAE), a microtubule inhibitor, directly into tumor cells. Upon internalization, MMAE disrupts microtubule organization, inhibits proper cell division, and ultimately results in tumor cell death, providing a targeted strategy in oncology research.
Purity:
0.987
CAS Number:
[2764774-90-3]
Target:
Antibody-Drug Conjugates (ADCs)|||Integrin
* VAT and and shipping costs not included. Errors and price changes excepted
